Loading organizations...
§ Venture Capital · San Francisco, CA, USA
Early-stage venture capital firm investing in biotechnology and bioeconomy companies for sustainable solutions using biological processes.
Key people at Bioeconomy Capital.
Bioeconomy Capital is a Seattle, Washington-based early-stage venture capital firm that invests in biotechnology, synthetic biology, and advanced bio-manufacturing infrastructure companies. The firm, which recently announced a rebrand to Planetary Technologies, targets seed through Series B funding rounds for startups developing scalable biological processes to reduce global fossil fuel reliance. Operating as a boutique investment vehicle, the organization has completed 15 total investments across the life sciences, agriculture, energy, and software sectors. Its portfolio features recognizable names such as artificial intelligence-driven protein design company Arzeda, which raised a $21 million Series B funding round. Additionally, the firm backed Lumen Bioscience, a biotechnology enterprise that secured a $16 million grant from the National Institutes of Health to develop an edible malaria vaccine. Bioeconomy Capital was founded in 2014 by managing directors Rob Carlson and Rik Wehbring.
Key people at Bioeconomy Capital.
Bioeconomy Capital is an early-stage venture capital firm focused on accelerating the biotechnology revolution by investing in companies that harness biological processes to create sustainable solutions. Its mission is to drive innovation in the bioeconomy by supporting startups that develop technologies enabling biological engineering and production, aiming to reduce reliance on fossil fuels and promote environmental sustainability. The firm primarily invests in sectors such as agriculture, energy, materials, and healthcare, providing both capital and strategic guidance to help these companies commercialize bio-based technologies and foster a resilient global economy[1][2].
Founded around the mid-2010s and based in Seattle, Bioeconomy Capital was established by experienced fund managers and scientists, including Dr. Rob Carlson, a recognized expert in biological engineering and economic analysis. The firm emerged from the recognition that advances in biology could profoundly improve the human condition and contribute significantly to the global economy. Early traction came from Fund 1, which completed $8.3 million in investments across six companies building critical infrastructure for the bioeconomy, demonstrating measurable impact within just a few years of investment[2][7][8].
Bioeconomy Capital rides the global trend toward sustainability and the bioeconomy, where biological technologies replace traditional fossil fuel-based processes. The timing is critical as climate change concerns and resource constraints drive demand for bio-based alternatives in agriculture, materials, and energy. Market forces such as advances in DNA reading/writing technologies and growing investor interest in climate tech favor Bioeconomy Capital’s focus. By nurturing foundational bioengineering companies, the firm helps build the infrastructure for a rapidly expanding bioeconomy, influencing both the startup ecosystem and broader industrial transformation[1][2][8].
Looking ahead, Bioeconomy Capital is poised to continue leading early-stage investments that underpin the bioeconomy’s growth. Trends such as synthetic biology, green chemistry, and scalable bio-based manufacturing will shape its portfolio evolution. As biological technologies mature and achieve cost parity with incumbents, the firm’s influence will likely expand, driving both environmental impact and economic value. Its proprietary blueprint and expert management position it well to capitalize on the accelerating biotech revolution and to foster a sustainable industrial future[2][8].
Bioeconomy Capital has 10 tracked investments across 7 companies. The latest tracked deal is $46.0M Series A in The Nuclear Company in May 2025.
